Concurrent Cetuximab and Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Clinical Cancer Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Phase II multi-institutional clinical trial result of concurrent cetuximab and nivolumab in recurrent and/or metastatic head and neck squamous cell carcinoma
Clin. Cancer Res 2022 Mar 28;[EPub Ahead of Print], CH Chung, J Li, CE Steuer, P Bhateja, M Johnson, J Masannat, MI Poole, F Song, JC Hernandez-Prera, H Molina, BM Wenig, S Kumar, C Kuperwasser, PJ Stephens, JM Farinhas, DM Shin, JA Kish, J Muzaffar, K Kirtane, JW Rocco, MJ Schell, NF Saba, M BonomiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.